DEF 14A: Cellectar Biosciences Seeks Stockholder Approval for Incentive Plan Expansion and Director Elections

Cellectar Biosciences is holding its annual meeting on June 14, 2024, to vote on director elections, an increase in common stock available for issuance under the 2021 Stock Incentive Plan, ratification of the independent accounting firm, and executive compensation.

Summary

• Cellectar Biosciences will hold its 2024 Annual Meeting of Stockholders virtually on June 14, 2024.
• Stockholders will vote on the election of two Class I directors, Dr. Asher Chanan-Khan and Mr. John Neis, for a three-year term expiring in 2027.
• A key proposal is to approve an increase of 7,000,000 shares of common stock available for issuance under the 2021 Stock Incentive Plan.
• Stockholders will also vote to ratify the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024.
• Additionally, there will be a non-binding advisory vote to approve named executive officer compensation.
• The Board recommends voting FOR all proposals and the election of the director nominees.
• The record date for determining stockholders eligible to vote is April 24, 2024.
• As of the record date, there were 35,848,924 shares of common stock outstanding.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily focusing on procedural matters related to the annual meeting. The request for increased shares for the incentive plan could be seen as slightly positive, indicating growth and the need to attract talent, but also carries a dilution risk.

Positives

• The Board is actively seeking stockholder input on key decisions through the proxy voting process.
• The virtual meeting format is expected to encourage higher levels of stockholder participation.
• The Board has determined that, with the exception of Mr. Caruso, all of the members of our Board of Directors are independent directors under the applicable rules and regulations of the SEC and the listing requirements of the Nasdaq Stock Market.

Negatives

• Approval of the 7,000,000 share increase to the 2021 Stock Incentive Plan will result in approximately 26% dilution.

Risks

• If the amendment to the 2021 Plan is not approved by stockholders, the Company may not have sufficient shares available to meet its needs for the next year.
• The Company incurred a net loss of $37,983,496 in 2023.

Future Outlook

The Company seeks to continue providing equity compensation to attract, retain, and motivate current and prospective directors, officers, employees, and consultants.

Industry Context

As a clinical phase biopharmaceutical business, the Company relies heavily upon stock incentive compensation to attract and retain key employees and other key service providers and has limited financial resources to utilize cash compensation as an alternative means to attract and retain such individuals.

Related Party Transactions

• On September 5, 2023, the Company entered into a securities purchase agreement with certain accredited investors, including ADAR1 Partners, LP, certain entities associated with AIGH Capital Management LLC, Laurence W. Lytton, certain entities associated with Nantahala Capital Management, LLC and certain entities associated with Rosalind Advisors, Inc., pursuant to which the Company agreed to issue and sell, in a private placement, (i) 1,225 shares of Series E-1 Convertible Voting Preferred Stock, par value $0.0001 per share (the Series E-1 Preferred Stock), (ii) Tranche A Warrants (the Tranche A Warrants) to acquire shares of Series E-3 Convertible Voting Preferred Stock and (iii) Tranche B Warrants (the Tranche B Warrants, together with the Tranche A Warrants, the Warrants) to acquire shares of Series E-4 Convertible Voting Preferred Stock, par value $0.00001 per share (the Series E-4 Preferred Stock and together with the Series E-3 Preferred Stock, the Warrant Shares) for an aggregate offering price of $24.5 million.
• ADAR1 Partners, LP, AIGH Capital Management LLC, Laurence W. Lytton, Nantahala Capital Management, LLC and Rosalind Advisors, Inc. are beneficial owners of more than 5% of our outstanding capital stock.

Stakeholder Impact

• Approval of the stock incentive plan increase could impact shareholders through potential dilution.
• Executive compensation decisions impact executive officers.
• The selection of directors impacts the overall governance and strategic direction of the company.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The Company will announce preliminary voting results at the Annual Meeting and disclose final results in a Form 8-K filing.

Key Dates

Keywords

proxy statement, annual meeting, stock incentive plan, director election, executive compensation, Baker Tilly, common stock, corporate governance, Cellectar Biosciences